🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Colgate-Palmolive shares get buy rating on recent strategic moves

EditorNatashya Angelica
Published 22/07/2024, 21:34
CL
-

On Monday, TD Cowen initiated coverage on shares of Colgate-Palmolive Company (NYSE:CL), assigning a Buy rating and setting a price target of $110.00 for the stock.

The firm highlighted Colgate-Palmolive's recent strategic moves, including the refocusing of its global innovation resources and the digitization of its infrastructure, which have allowed the company to fully leverage its science-based capabilities, particularly in the oral care and pet food segments.

The company has been experiencing accelerating business momentum, with notable volume growth in key markets. This growth trajectory is seen as a positive indicator for the stock's future performance. Despite Colgate-Palmolive's current premium valuation, TD Cowen anticipates further upside potential driven by positive sales and earnings per share (EPS) revisions.

Colgate-Palmolive's emphasis on innovation and digital transformation has been recognized as a factor that positions the company advantageously in its industry. The firm's decision to rate the stock as a Buy reflects confidence in Colgate-Palmolive's ability to sustain and build upon its current market performance.

Investors may find the firm's outlook on Colgate-Palmolive noteworthy, as it suggests continued growth and success in the consumer goods giant's core market areas. The price target of $110.00 represents the firm's expectation for the stock's value, informed by recent business developments and future prospects.

The initiation of coverage and the positive outlook on Colgate-Palmolive by TD Cowen could influence market perception and investor decisions regarding the company's shares. Colgate-Palmolive continues to trade on the New York Stock Exchange, with investors keeping a close eye on its performance in light of the new coverage.

In other recent news, Colgate-Palmolive has been the subject of a number of significant developments. The company's Q1 2024 results showcased a robust 6% net sales growth and a substantial improvement in gross margins by 310 basis points, despite foreign exchange challenges. This strong performance sets the stage for a promising year, with projected mid to high single-digit base business earnings per share growth.

Several analysts have also updated their outlook on the company. Deutsche Bank (ETR:DBKGn) raised its price target for Colgate-Palmolive to $104 from $98, maintaining a Buy rating, while Morgan Stanley (NYSE:MS) increased its price target to $103 from $101, citing confidence in the company's ability to sustain high operational and earnings growth.

Similarly, Argus raised its price target to $107.00 from $97.00, maintaining a Buy rating due to the company's consistent organic sales growth and commitment to product innovation.

In other company news, Jeff Duncan, representative of South Carolina's 3rd congressional district, sold stocks in Colgate-Palmolive from his Raymond James IRA, reflecting a shift from individual stocks to a more diversified retirement savings plan. These recent developments underscore the active interest and ongoing changes in Colgate-Palmolive's market performance and strategic positioning.

InvestingPro Insights

As Colgate-Palmolive (NYSE:CL) garners a favorable outlook from TD Cowen, real-time data from InvestingPro complements this positive sentiment.

With a market capitalization of $80.43 billion and a robust gross profit margin of 59.0% in the last twelve months as of Q1 2024, Colgate-Palmolive demonstrates strong financial health. This is underscored by the company's impressive ability to maintain dividend payments for 54 consecutive years, which is a testament to its financial stability and commitment to shareholder returns.

An InvestingPro Tip worth noting is Colgate-Palmolive's low PEG ratio of 0.48 for the last twelve months as of Q1 2024, which suggests that the stock may be undervalued relative to its earnings growth.

Moreover, the company's trading at a high revenue valuation multiple indicates investor confidence in its revenue-generating capabilities. With analysts revising their earnings upwards for the upcoming period, there's an anticipation of continued profitability, supported by the fact that the company has been profitable over the last twelve months.

For investors looking to delve deeper into Colgate-Palmolive's financials and market position, InvestingPro offers additional insights. There are 6 more InvestingPro Tips available for Colgate-Palmolive, which can be accessed by using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. These tips provide valuable information for making informed investment decisions, and can be found at: https://www.investing.com/pro/CL.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.